Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'

Evid Based Med. 2016 Jun;21(3):83-6. doi: 10.1136/ebmed-2015-110325. Epub 2015 Dec 30.
No abstract available

MeSH terms

  • Aminophenols / adverse effects
  • Aminophenols / therapeutic use*
  • Aminopyridines / adverse effects
  • Aminopyridines / therapeutic use*
  • Benzodioxoles / adverse effects
  • Benzodioxoles / therapeutic use*
  • Body Mass Index
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / physiopathology
  • Data Interpretation, Statistical
  • Disease Progression
  • Drug Approval
  • Drug Combinations
  • Drug Costs
  • Evidence-Based Medicine*
  • Humans
  • Lung / physiopathology
  • Quinolones / adverse effects
  • Quinolones / therapeutic use*
  • Surveys and Questionnaires
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Aminophenols
  • Aminopyridines
  • Benzodioxoles
  • Drug Combinations
  • Quinolones
  • lumacaftor, ivacaftor drug combination